Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides.

[1]  W. Cowden,et al.  Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. , 1999, Cancer research.

[2]  D. Abendschein,et al.  Anticoagulant and antithrombotic activity of maltodapoh, a novel sulfated tetrasaccharide. , 1999, The Journal of pharmacology and experimental therapeutics.

[3]  D. Mungall,et al.  Developing and testing a system to improve the quality of heparin anticoagulation in patients with acute cardiac syndromes. , 1998, The American journal of cardiology.

[4]  H. Ye,et al.  Comparative effects of heparin and the sulfatoid GM1474 on coagulation parameters in plasma and blood from various species. , 1998, General pharmacology.

[5]  P Théroux,et al.  Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. , 1998, Circulation.

[6]  D. Mungall,et al.  Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements. , 1997, Archives of internal medicine.

[7]  A. Iorio,et al.  Effect of dermatan sulphate on activated partial thromboplastin time determined with different reagents. , 1997, Haemostasis.

[8]  J. T. ten Cate,et al.  Clinical applications of new antithrombotic agents , 1996, Annals of Hematology.

[9]  T. Uryu,et al.  Synthesis of sulfated alkyl malto- and laminara-oligosaccharides with potent inhibitory effects on AIDS virus infection. , 1994, Carbohydrate research.

[10]  Richard Kijowski,et al.  Protamine sulfate neutralization of the anticoagulant activity of Aprosulate, a synthetic sulfated lactobionic acid amide. , 1994, Thrombosis research.

[11]  W. Raake,et al.  Derivatives of bis-aldonic acid amides and their anticoagulant and antithrombotic properties. , 1994, Seminars in thrombosis and hemostasis.

[12]  S. Olson,et al.  Regulation of Thrombin Activity by Antithrombin and Heparin , 1994, Seminars in thrombosis and hemostasis.

[13]  U. Lindahl,et al.  Glycosaminoglycans and the regulation of blood coagulation. , 1993, The Biochemical journal.

[14]  J. Fareed,et al.  Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues. , 1993, Seminars in thrombosis and hemostasis.

[15]  G. Agnelli,et al.  A Randomised, Double-Blind, Placebo-Controlled Trial of Dermatan Sulphate for Prevention of Deep Vein Thrombosis in Hip Fracture , 1992, Thrombosis and Haemostasis.

[16]  L. M. Smith,et al.  Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082. , 1992, European journal of biochemistry.

[17]  J. Fareed,et al.  Influence of Hypersulfated Lactobionic Acid Amides on Tissue Plasminogen Activator Release , 1991, Seminars in thrombosis and hemostasis.

[18]  R. Klauser.  Interaction of the sulfated lactobionic acid amide LW 10082 with thrombin and its endogenous inhibitors. , 1991, Thrombosis research.

[19]  J. Hirsh.  Drug therapy : heparin , 1991 .

[20]  D. Tollefsen,et al.  Effect of low molecular weight heparin preparations on the inhibition of thrombin by heparin cofactor II. , 1990, Seminars in thrombosis and hemostasis.

[21]  D. Tollefsen,et al.  Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II. , 1990, The Journal of biological chemistry.

[22]  D. Lane,et al.  Heparin: Chemical and Biological Properties Clinical Applications , 1989 .

[23]  U. Abildgaard,et al.  Heparin cofactor IIOslo. Mutation of Arg-189 to His decreases the affinity for dermatan sulfate. , 1989, The Journal of biological chemistry.

[24]  J. Hirsh,et al.  The haemorrhagic and antithrombotic effects of dermatan sulphate , 1986, British journal of haematology.

[25]  G. Gogstad,et al.  Turbidimetric determination of prothrombin time by clotting in a centrifugal analyzer. , 1986, Clinical chemistry.

[26]  D. Tollefsen,et al.  Molecular size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II. , 1986, The Journal of biological chemistry.

[27]  S. Machin,et al.  Laboratory investigation of platelet function: a review of methodology. , 1986, Journal of clinical pathology.

[28]  H. Lill,et al.  Development of a photometric assay for activated partial thromboplastin time and its application to the Cobas Bio centrifugal analyzer. , 1985, Thrombosis research.

[29]  D. Tollefsen,et al.  Activation of heparin cofactor II by dermatan sulfate. , 1983, The Journal of biological chemistry.

[30]  H. Arnesen,et al.  The euglobulin clot lysis time, a rapid and sensitive method for the assay of fibrinolytic activity after venous stasis. , 2009, Scandinavian journal of haematology.

[31]  G. Kaczorowski,et al.  Characterization of a phosphorylated pentasaccharide isolated from Hansenula holstii NRRL Y-2448 phosphomannan. , 1973, Biochemistry.